aTYR PHARMA Business Summary

aTyr Pharma Inc. (ATYR) is a clinical-stage biotherapeutics company pioneering the development of first-in-class medicines derived from its proprietary tRNA synthetase biology platform. The company’s business model centers on the discovery and clinical advancement of "Physiocrines"—extracellular signaling proteins that regulate immune and fibrotic pathways. Revenue is primarily generated through strategic licensing and development collaborations, most notably a partnership with Kyorin Pharmaceutical Co., Ltd. for the development of its lead candidate, efzofitimod, in Japan. Efzofitimod, a selective neuropilin-2 (NRP2) modulator, is currently the company's primary value driver, targeting interstitial lung diseases (ILD) such as pulmonary sarcoidosis and systemic sclerosis-associated ILD. As of early 2026, aTyr is navigating a critical regulatory phase following a Phase 3 study that missed its primary endpoint but demonstrated significant clinical benefit in secondary measures, leading to a scheduled FDA Type C meeting in April 2026. The company competes in the high-stakes immunology and fibrosis space against firms like Crinetics Pharmaceuticals, Rallybio, and Ventyx Biosciences, positioning itself as a niche leader in tRNA-based immunomodulation. The company was co-founded by world-renowned scientists Paul Schimmel, Ph.D., a professor at Scripps Research and co-founder of biotech giants like Alnylam and Alkermes, and Xiang-Lei Yang, Ph.D., a leading expert in aminoacyl tRNA synthetase research. The leadership team is headed by President and CEO Sanjay S. Shukla, M.D., M.S., who has led the firm since 2017 and previously served as its Chief Medical Officer. Key executives include Jill M. Broadfoot (CFO), Leslie Nangle, Ph.D. (VP, Research), and Darin Lee, Ph.D., who was appointed VP of Technical Operations in late 2025. The company is supported by a veteran board chaired by Timothy P. Coughlin and includes notable directors such as Jane Gross and Svetlana Lucas. aTyr has attracted significant institutional backing from premier life science investors, including Polaris Partners, Sofinnova Investments, Alta Partners, and Deerfield Management.